Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 366 across all filing types
Latest filing 2025-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Medipost. It outlines the date, location, and agenda items for the upcoming Annual General Meeting, including the approval of financial statements, election of directors, and amendments to business purposes. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and request their participation/votes.
2025-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by MediPost regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date despite regulatory recommendations for dispersion. Since this is a specific regulatory disclosure regarding meeting logistics and does not contain the actual proxy materials, financial results, or voting results, it falls under the general regulatory filing category.
2025-03-12 Korean
유상증자결정(종속회사의주요경영사항)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from Medipost regarding a capital increase (paid-in capital increase) for its subsidiary, MEDIPOST, Inc. It details the number of shares, purpose of funds, and board resolution details. This falls under the category of capital and financing updates as it describes a specific fundraising activity.
2025-03-12 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (a Non-Deal Roadshow). It provides details such as the date, location, purpose, and participants. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate disclosure.
2025-03-06 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from MediPost regarding a significant change in sales or profit/loss structure (a mandatory disclosure requirement in the Korean market). It provides preliminary financial results (revenue, operating profit, net income) comparing the current fiscal year to the previous one, along with the reasons for the variance. Since this is an initial announcement of financial performance highlights rather than a full annual report or a simple report publication notice, it falls under the Earnings Release (ER) category. FY 2024
2025-02-19 Korean
[기재정정]기타경영사항(자율공시) (전환우선주 전환가액 조정)
Share Issue/Capital Change Classification · 95% confidence The document is a regulatory filing from Medipost regarding the adjustment of the conversion price for convertible preferred shares. It details the change in conversion price and the resulting impact on the number of convertible shares. This type of disclosure, which relates to capital structure changes and financial instruments, falls under the 'Share Issue/Capital Change' category as it directly impacts the company's equity structure and potential share dilution.
2025-02-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.